Hundreds of billions of diabetes medical market, new members!

"Pharmaceutical Network Market Analysis" Hua-Li Pharmaceuticals announced on October 14, after the drug market license holder (MAH) system audit and on-site verification, the company has been issued by the Shanghai Municipal Drug Administration in the study of the global innovative drug Dozagliatin "Drug Production License."
clinical study data show that during the corresponding treatment cycle, Dozagliatin has shown significant stability and safety, and is expected to fundamentally treat diabetes.
according to the International Diabetes Federation, the number of adults with diabetes worldwide reached 463 million in 2019, and the number is expected to increase significantly in the future, reaching 700 million by 2045.
, the number of people with diabetes in China is as high as 116.4 million.
and about 95 percent of people with diabetes are type 2 diabetics.
, according to the Frost Sullivan report, the rapid urbanization of our country has led to an increase in obesity rates as a result of an increasing number of people developing unhealthy diets and increasingly sedentary lifestyles.
addition, our country is entering an ageing society, and the number of people over the age of 65 is increasing.
this situation, the number of people with diabetes will increase significantly, resulting in an increase in the number of people with type 2 diabetes.
the future, with the increase of medical insurance coverage and consumption upgrading, the diagnosis rate and treatment rate of diabetic patients will increase, and the size of China's diabetes medical market is expected to exceed 100 billion in the next 3 years.
, if successfully approved, it will be a new diabetes drug that fixes impaired blood sugar sensors for people with type 2 diabetes.
clinical trials have shown that Dozagliatin, which can be used alone and in a joint use with existing anti-diabetic drugs, has high commercial value and will further benefit people with diabetes in the country.
it is understood that in terms of commercial cooperation, Hua-Li Pharmaceuticals and Bayer announced on August 17 to establish a strategic cooperation agreement on Dozagliatin in China.
is responsible for clinical development, production and supply, first-class distribution, registration and drug alerting, while Bayer is responsible for its marketing, promotion and medical education activities in China.
according to the newly revised Drug Administration Law and the Measures for the Supervision and Administration of Drug Production, holders, as the main body engaged in drug production, are required to obtain a Drug Production License, whether producing on their own or commissioned.
It is understood that Hua-Li Pharmaceuticals is the first biotechnology company to obtain a Pharmaceutical Production License since the implementation of the new Version of the Drug Administration Law on December 1, 2019, which means that Hua-Li Pharmaceuticals can entrust the existing CMO company to carry out drug production after the approval of Dozagliatin into the commercialization stage, which fully guarantees the supply of drugs after the market.
, the Drug Production License will further accelerate the process of applying for the listing of new drugs (NDA) for Huali Pharmaceuticals, in preparation for the commercial production and supply of post-market products.
fact, recent policies have also been good for the development of innovative drugs.
such as the recently introduced 2020 health insurance catalog adjustment program, will support innovative drugs, newly listed drugs in the current year approved, commercial listing in the current year, the possibility of entering the health insurance catalog in that year.
industry believes this also means that Dozagliatin is likely to be approved that year, currently commercially listed, and entered the health insurance directory that year.